Visionary Managing Partner, Jeffry Weinhuff, Appointed to Chairman of Orasis
Orasis announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors.
Orasis CEO, Elad Kedar, Interviewed at OIS and AAO
Elad Kedar discusses the presbyopia market and the Orasis product.
Ophthalmology Management Article on “Partnering for Innovation”
Jeffry Weinhuff, discusses how ophthalmologists, entrepreneurs, strategic buyers, and venture capitalists partner for success.
Ophthalmology Management Spotlight on Visionary Portfolio company Tear Film Innovations
Visionary’s portfolio company Tear Film Innovations’ iLux spotlighted in an Ophthalmology Management Article about Treatment of Meibomian gland disfunction (MGD).
Orasis Pharmaceuticals completes $13MM Series B financing led by Visionary Ventures
Orasis Pharmaceuticals completes $13MM Series B financing led by Visionary Ventures, with participation from Sequoia Capital, SBI (Japan) Innovation Ventures, LifeSci Venture Partners, and other private investors
Tear Film Innovations completes $8.5MM Series B financing co-led by Visionary Ventures and Bluestem Capital
Tear Film Innovations completes $8.5MM Series B financing co-led by Visionary Ventures and Bluestem Capital
Tear Film Innovations completes $9MM Series A financing co-led by Visionary Ventures and Tigris Ventures
Tear Film Innovations completes $9MM Series A financing co-led by Visionary Ventures and Tigris Ventures
PWC Healthcare MoneyTree Report Q2 2017 Names Visionary Ventures the Number 3 Most Active Venture Fund in Healthcare
PWC Healthcare MoneyTree Report Q2 2017 Names Visionary Ventures the Number 3 Most Active Venture Fund in Healthcare.
IanTECH Completes Financing co-led by Visionary Ventures and GHIF
Funding for IanTECH’s Next Generation Ophthalmic Device Supports Goal to Alleviate Cataract-induced Blindness in 25 Million.
TearClear Completes $4.5MM Series A Financing co-led by Visionary Ventures
TearClear closes series A financing and introduces leadership team of accomplished ophthalmology veterans with the proceeds going to advance the development of the Company’s delivery system for preservative-free ophthalmic drugs.